Efficacy and safety of Remdesivir treatment for acute respiratory syndrome caused by SARS-COV-2 in patients admitted to a general hospital.
Date
2021-02-21
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Abstract
Background An efficient approach to drug discovery is to test whether existing antiviral drugs are effective in treating viral infections related. SARS-CoV2 is known to belong to the SARS-CoV family and the Middle East CoV Respiratory Syndrome (MERS-CoV). In animal models, administration of GS-5734 significantly reduced the viral load of pulmonary SARS-CoV and improved clinical signs of disease, as well as respiratory function. The objective of our review and metanalisis is to evaluate the efficacy and safety of remdesivir, treatment of acute respiratory syndrome caused by COVID-19 in patients who are admitted to a general hospital
Methods PubMed / Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and grey literature were searched. We included studies of patients adults over 18 years of age with acute respiratory syndrome withSARS-CoV2. The primary objective was to assess the rate mortality with remdesivir vs placebo. The secondary objective was to assess the rate general and severe side effects.
Results Overall mortality was lower in the group receiving remdesivir in comparison to the placebo group (OR 0.65; 95% CI, 0.44-0.96; I2 55%). The risk of adverse events was (OR 1.01; 95% CI, 0.79-1.28; I2 0%) and that of severe adverse events was (OR 0.71; 95% CI, 0.55-0.92; I2 0%) remdesivir compared to placebo.
Conclusions The use of remdesivir for the treatment of SARS-COV2 acute respiratory syndrome in patients admitted to a general hospital is based on a weak recommendation, because the quality of the evidence is low.
Description
EBMFBT Open Access
item.page.type
Article
item.page.format
Keywords
Remdesivir, SARS-COV-2, Meta-analysis